235 related articles for article (PubMed ID: 30611710)
1. Noncoding RNA genes in cancer pathogenesis.
Pekarsky Y; Croce CM
Adv Biol Regul; 2019 Jan; 71():219-223. PubMed ID: 30611710
[TBL] [Abstract][Full Text] [Related]
2.
Rassenti LZ; Balatti V; Ghia EM; Palamarchuk A; Tomasello L; Fadda P; Pekarsky Y; Widhopf GF; Kipps TJ; Croce CM
Proc Natl Acad Sci U S A; 2017 Oct; 114(40):10731-10736. PubMed ID: 28923920
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA Dysregulation to Identify Novel Therapeutic Targets.
Croce CM
Curr Top Microbiol Immunol; 2017; 407():191-203. PubMed ID: 28653191
[TBL] [Abstract][Full Text] [Related]
4. BCL2 and miR-15/16: from gene discovery to treatment.
Pekarsky Y; Balatti V; Croce CM
Cell Death Differ; 2018 Jan; 25(1):21-26. PubMed ID: 28984869
[TBL] [Abstract][Full Text] [Related]
5. High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia.
Ghia EM; Rassenti LZ; Choi MY; Quijada-Álamo M; Chu E; Widhopf GF; Kipps TJ
Leukemia; 2022 Jun; 36(6):1609-1618. PubMed ID: 35418613
[TBL] [Abstract][Full Text] [Related]
6. Potential of BCL2 as a target for chronic lymphocytic leukemia treatment.
Moia R; Diop F; Favini C; Kodipad AA; Gaidano G
Expert Rev Hematol; 2018 May; 11(5):391-402. PubMed ID: 29561706
[TBL] [Abstract][Full Text] [Related]
7. NF-κB-p62-NRF2 survival signaling is associated with high ROR1 expression in chronic lymphocytic leukemia.
Sanchez-Lopez E; Ghia EM; Antonucci L; Sharma N; Rassenti LZ; Xu J; Sun B; Kipps TJ; Karin M
Cell Death Differ; 2020 Jul; 27(7):2206-2216. PubMed ID: 31992855
[TBL] [Abstract][Full Text] [Related]
8. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies.
Ten Hacken E; Valentin R; Regis FFD; Sun J; Yin S; Werner L; Deng J; Gruber M; Wong J; Zheng M; Gill AL; Seiler M; Smith P; Thomas M; Buonamici S; Ghia EM; Kim E; Rassenti LZ; Burger JA; Kipps TJ; Meyerson ML; Bachireddy P; Wang L; Reed R; Neuberg D; Carrasco RD; Brooks AN; Letai A; Davids MS; Wu CJ
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282833
[TBL] [Abstract][Full Text] [Related]
9. Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia.
Roberts AW; Stilgenbauer S; Seymour JF; Huang DCS
Clin Cancer Res; 2017 Aug; 23(16):4527-4533. PubMed ID: 28100580
[TBL] [Abstract][Full Text] [Related]
10. miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies.
Al-Harbi S; Choudhary GS; Ebron JS; Hill BT; Vivekanathan N; Ting AH; Radivoyevitch T; Smith MR; Shukla GC; Almasan A
Mol Cancer; 2015 Nov; 14():185. PubMed ID: 26537004
[TBL] [Abstract][Full Text] [Related]
11. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
[TBL] [Abstract][Full Text] [Related]
12. Role of miR-15/16 in CLL.
Pekarsky Y; Croce CM
Cell Death Differ; 2015 Jan; 22(1):6-11. PubMed ID: 24971479
[TBL] [Abstract][Full Text] [Related]
13. ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model.
Chiang CL; Goswami S; Frissora FW; Xie Z; Yan PS; Bundschuh R; Walker LA; Huang X; Mani R; Mo XM; Baskar S; Rader C; Phelps MA; Marcucci G; Byrd JC; Lee LJ; Muthusamy N
Blood; 2019 Aug; 134(5):432-444. PubMed ID: 31151986
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA dysregulation and multi-targeted therapy for cancer treatment.
Balatti V; Croce CM
Adv Biol Regul; 2020 Jan; 75():100669. PubMed ID: 31640928
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax.
Avsec D; Škrlj Miklavčič M; Burnik T; Kandušer M; Bizjak M; Podgornik H; Mlinarič-Raščan I
Cell Death Dis; 2022 Oct; 13(10):860. PubMed ID: 36209148
[TBL] [Abstract][Full Text] [Related]
16. Venetoclax for the Treatment of Chronic Lymphocytic Leukemia.
Eradat H
Curr Hematol Malig Rep; 2019 Oct; 14(5):469-476. PubMed ID: 31512151
[TBL] [Abstract][Full Text] [Related]
17. Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.
Blombery P; Anderson MA; Gong JN; Thijssen R; Birkinshaw RW; Thompson ER; Teh CE; Nguyen T; Xu Z; Flensburg C; Lew TE; Majewski IJ; Gray DHD; Westerman DA; Tam CS; Seymour JF; Czabotar PE; Huang DCS; Roberts AW
Cancer Discov; 2019 Mar; 9(3):342-353. PubMed ID: 30514704
[TBL] [Abstract][Full Text] [Related]
18. Venetoclax, the first BCL-2 inhibitor for use in patients with chronic lymphocytic leukemia.
Seymour J
Clin Adv Hematol Oncol; 2019 Aug; 17(8):440-443. PubMed ID: 31449511
[No Abstract] [Full Text] [Related]
19. Apoptotic effect of berberine via Bcl-2, ROR1, and mir-21 in patients with B-chronic lymphocytic leukemia.
Mohammadlou M; Abdollahi M; Hemati M; Baharlou R; Doulabi EM; Pashaei M; Ghahremanfard F; Faranoush M; Kokhaei P
Phytother Res; 2021 Apr; 35(4):2025-2033. PubMed ID: 33174291
[TBL] [Abstract][Full Text] [Related]
20. miR-15 and miR-16 induce apoptosis by targeting BCL2.
Cimmino A; Calin GA; Fabbri M; Iorio MV; Ferracin M; Shimizu M; Wojcik SE; Aqeilan RI; Zupo S; Dono M; Rassenti L; Alder H; Volinia S; Liu CG; Kipps TJ; Negrini M; Croce CM
Proc Natl Acad Sci U S A; 2005 Sep; 102(39):13944-9. PubMed ID: 16166262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
